Results 11 to 20 of about 2,204,307 (197)

A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide

Nature Communications, 2017
The antibiotic pyrazinamide is central to tuberculosis treatment regimens, globally. Despite its efficacy, resistance to the drug is increasing. Here, Eric Rubin and colleagues characterise the genetic basis of pyrazinamide resistance.
Adam N. Yadon, Kashmeel Maharaj, John H. Adamson, Yi-Pin Lai, James C. Sacchettini, Thomas R. Ioerger, Eric J. Rubin, Alexander S. Pym   +7 more
doaj   +7 more sources

Structure guided prediction of Pyrazinamide resistance mutations in pncA. [PDF]

Sci Rep, 2020
AbstractPyrazinamide plays an important role in tuberculosis treatment; however, its use is complicated by side-effects and challenges with reliable drug susceptibility testing. Resistance to pyrazinamide is largely driven by mutations in pyrazinamidase (pncA), responsible for drug activation, but genetic heterogeneity has hindered development of a ...
Karmakar M, Rodrigues CHM, Horan K, Denholm JT, Ascher DB.   +4 more
europepmc   +15 more sources

Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis. [PDF]

Journal of Clinical Microbiology, 2022
: Pyrazinamide is an important component of both drug-susceptible and drug-resistant tuberculosis treatment regimens. Although approximately 50% of rifampin-resistant isolates are also resistant to pyrazinamide, pyrazinamide susceptibility testing is not
Robin M. Warren, David M Engelthaler, Tim H. Heupink   +2 more
exaly   +4 more sources

Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan [PDF]

Clinical Microbiology and Infection, 2010
Thirty-six multidrug-resistant (MDR) Mycobacterium tuberculosis isolates collected in Japan were examined for pyrazinamide susceptibility and pyrazinamidase activity, and analysed by pncA sequencing and a hybridization-based line probe assay (LiPA), which was used to detect pncA mutations for the rapid identification of pyrazinamide-resistant isolates.
Ando, H., Mitarai, S., Kondo, Y., Suetake, T., Sekiguchi, J.-I., Kato, S., Mori, T., Kirikae, T.   +7 more
openaire   +4 more sources

Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study [PDF]

mBio, 2014
Pyrazinamide (PZA) is a prodrug that is converted to pyrazinoic acid by the enzyme pyrazinamidase, encoded by the pncA gene in Mycobacterium tuberculosis.
Paolo Miotto, Andrea M. Cabibbe, Silke Feuerriegel, Nicola Casali, Francis Drobniewski, Yulia Rodionova, Daiva Bakonyte, Petras Stakenas, Edita Pimkina, Ewa Augustynowicz-Kopeć, Massimo Degano, Alessandro Ambrosi, Sven Hoffner, Mikael Mansjö, Jim Werngren, Sabine Rüsch-Gerdes, Stefan Niemann, Daniela M. Cirillo   +17 more
doaj   +4 more sources

Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China

BMC Infectious Diseases, 2020
Background Pyrazinamide still may be a useful drug for treatment of rifampin-resistant (RR-TB) or multidrug-resistant tuberculosis (MDR-TB) in China while awaiting scale up of new drugs and regimens including bedaquiline and linezolid.
Hui Xia, Susan van den Hof, Frank Cobelens, Yang Zhou, Bing Zhao, Shengfen Wang, Yanlin Zhao   +6 more
doaj   +2 more sources

Colorimetric methods for rapid determination of pyrazinamide resistance

International Journal of Mycobacteriology, 2020
Background: Because pyrazinamide (PZA) is only effective for Mycobacterium tuberculosis at an acidic pH, susceptibility tests are more difficult to perform than those for other anti-tuberculosis (TB) drugs.
Ahmet Ugur Akbal, Belma Durupinar, Ahmet Yilmaz Coban   +2 more
doaj   +3 more sources

Pyrazinamide Resistance: A Major Cause of Switching Shorter to Longer Bedaquiline-based Regimens in Multidrug-resistant Tuberculosis Patients

International Journal of Mycobacteriology
Background: All-oral regimens, including bedaquiline, are now standard in shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB). Resistance or intolerance to drugs in STR often necessitates a switch to longer treatment regimens (
Oki Nugraha Putra, Nur Indah, Telly Purnamasari, Adi Larasanti   +3 more
doaj   +2 more sources

Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis. [PDF]

Infect Drug Resist, 2022
Pyrazinamide (PZA) is a critical component of standardized chemotherapy for tuberculosis (TB) and is recommended for the treatment of multidrug-resistant (MDR) TB. We aimed to characterize mutations in pncA of M. tuberculosis and evaluate their diagnostic accuracy for PZA susceptibility in China.
Shi D, Zhou Q, Xu S, Zhu Y, Li H, Xu Y.
europepmc   +5 more sources

Prediction of pyrazinamide resistance in Mycobacterium tuberculosis using structure-based machine-learning approaches. [PDF]

JAC Antimicrob Resist
Background Pyrazinamide is one of four first-line antibiotics used to treat tuberculosis; however, antibiotic susceptibility testing for pyrazinamide is challenging.
Carter JJ, Walker TM, Walker AS, Whitfield MG, Morlock GP, Lynch CI, Adlard D, Peto TEA, Posey JE, Crook DW, Fowler PW.   +10 more
europepmc   +2 more sources